Germany’s Merck KGaA is paying $45 million upfront for rights to a potentially first-in-class drug for colorectal cancer (CRC) being developed by New York biotech Inspirna. The agreement gives Merck ...
NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today a licensing agreement with Merck KGaA, Darmstadt, ...
Merck KGaA has said it will be paying $45m upfront for licensing rights to Inspirna’s mid-stage colorectal cancer drug. The candidate, ompenaclid (RGX-202), is an oral inhibitor of the creatine ...
NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today data from the ongoing Phase 1b/2 study of ...
(MENAFN- AETOSWire) (BUSINESS WIRE ) -- Merck, a leading science and technology company, today announced a licensing agreement with Inspirna, Inc. (New York, NY) for ompenaclid (RGX-202), a ...
Inspirna to receive $45 million in upfront payment for ex-US exclusive license and US co-development option to ompenaclid and follow-on compounds Inspirna, Inc., a clinical stage biopharmaceutical ...
Encouraging efficacy and safety data for ompenaclid (RGX-202) in combination with FOLFIRI/BEV supports further development in second-line advanced or metastatic CRC Inspirna, Inc., a clinical stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results